Kitasamycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Kitasamycin
Accession Number
DB09309
Type
Small Molecule
Groups
Experimental
Description

Kitasamycin (INN) is a macrolide antibiotic. It is produced by Streptomyces kitasatoensis.

Structure
Thumb
Synonyms
  • Leucomycin
Product Ingredients
IngredientUNIICASInChI Key
Kitasamycin tartrateIPN75MD9DR37280-56-1LCDBILLRZFJKMN-RKYMYSRXSA-N
Categories
UNII
YX09Z4QW5Y
CAS number
1392-21-8
Weight
Average: 785.969
Monoisotopic: 785.456155841
Chemical Formula
C40H67NO14
InChI Key
IEMDOFXTVAPVLX-YWQHLDGFSA-N
InChI
InChI=1S/C40H67NO14/c1-22(2)18-30(45)53-38-26(6)51-32(21-40(38,7)48)54-35-25(5)52-39(34(47)33(35)41(8)9)55-36-27(16-17-42)19-23(3)28(43)15-13-11-12-14-24(4)50-31(46)20-29(44)37(36)49-10/h11-13,15,17,22-29,32-39,43-44,47-48H,14,16,18-21H2,1-10H3/b12-11+,15-13+/t23-,24-,25-,26+,27+,28+,29-,32+,33-,34-,35-,36+,37+,38+,39+,40-/m1/s1
IUPAC Name
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Kitasamycin.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Kitasamycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Kitasamycin.Experimental
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Kitasamycin.Approved, Illicit
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Kitasamycin.Approved, Illicit, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Kitasamycin.Experimental, Investigational
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Kitasamycin.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Kitasamycin.Approved
AmrinoneThe metabolism of Amrinone can be decreased when combined with Kitasamycin.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Atorvastatin.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Kitasamycin.Approved, Investigational
AzimilideThe metabolism of Azimilide can be decreased when combined with Kitasamycin.Investigational
BarnidipineThe metabolism of Barnidipine can be decreased when combined with Kitasamycin.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Kitasamycin.Investigational
BencyclaneThe metabolism of Bencyclane can be decreased when combined with Kitasamycin.Experimental
BenidipineThe metabolism of Benidipine can be decreased when combined with Kitasamycin.Approved, Investigational
BepridilThe metabolism of Bepridil can be decreased when combined with Kitasamycin.Approved, Withdrawn
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Kitasamycin.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Kitasamycin.Approved, Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Kitasamycin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Kitasamycin.Approved, Investigational
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be decreased when combined with Kitasamycin.Investigational
CaroverineThe metabolism of Caroverine can be decreased when combined with Kitasamycin.Experimental
CerivastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Cerivastatin.Withdrawn
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Kitasamycin.Approved, Investigational
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Kitasamycin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Kitasamycin.Approved, Investigational, Withdrawn
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Kitasamycin.Experimental
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Kitasamycin.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Kitasamycin.Experimental
DarodipineThe metabolism of Darodipine can be decreased when combined with Kitasamycin.Experimental
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Kitasamycin.Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Kitasamycin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Kitasamycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Kitasamycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Kitasamycin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Kitasamycin.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Kitasamycin.Approved
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Kitasamycin.Experimental
DisopyramideKitasamycin may increase the QTc-prolonging activities of Disopyramide.Approved
DotarizineThe metabolism of Dotarizine can be decreased when combined with Kitasamycin.Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Kitasamycin.Approved, Investigational
EperisoneThe metabolism of Eperisone can be decreased when combined with Kitasamycin.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Kitasamycin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Kitasamycin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Kitasamycin.Approved
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Kitasamycin.Approved, Illicit
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Kitasamycin.Withdrawn
FelodipineThe metabolism of Felodipine can be decreased when combined with Kitasamycin.Approved, Investigational
FendilineThe metabolism of Fendiline can be decreased when combined with Kitasamycin.Withdrawn
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Kitasamycin.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Kitasamycin.Approved
FluvastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Fluvastatin.Approved
GabapentinThe metabolism of Gabapentin can be decreased when combined with Kitasamycin.Approved, Investigational
GallopamilThe metabolism of Gallopamil can be decreased when combined with Kitasamycin.Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Kitasamycin.Experimental
IsradipineThe metabolism of Isradipine can be decreased when combined with Kitasamycin.Approved
LacidipineThe metabolism of Lacidipine can be decreased when combined with Kitasamycin.Approved, Investigational
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Kitasamycin.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Kitasamycin.Experimental
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Kitasamycin.Approved, Investigational
LidoflazineThe metabolism of Lidoflazine can be decreased when combined with Kitasamycin.Experimental
LovastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Lovastatin.Approved, Investigational
Magnesium SulfateThe metabolism of Magnesium Sulfate can be decreased when combined with Kitasamycin.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Kitasamycin.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Kitasamycin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Kitasamycin.Experimental
MevastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Mevastatin.Experimental
MibefradilThe metabolism of Mibefradil can be decreased when combined with Kitasamycin.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Kitasamycin.Approved, Illicit
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Kitasamycin.Investigational
NicardipineThe metabolism of Nicardipine can be decreased when combined with Kitasamycin.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Kitasamycin.Approved
NiguldipineThe metabolism of Niguldipine can be decreased when combined with Kitasamycin.Experimental
NiludipineThe metabolism of Niludipine can be decreased when combined with Kitasamycin.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Kitasamycin.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be decreased when combined with Kitasamycin.Approved, Investigational, Withdrawn
NimodipineThe metabolism of Nimodipine can be decreased when combined with Kitasamycin.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Kitasamycin.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Kitasamycin.Approved, Investigational
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Kitasamycin.Experimental, Investigational
OtiloniumThe metabolism of Otilonium can be decreased when combined with Kitasamycin.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Kitasamycin.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Kitasamycin.Approved, Investigational
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Kitasamycin.Experimental
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Kitasamycin.Approved, Investigational
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Kitasamycin.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Kitasamycin.Approved
PimozideKitasamycin may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Kitasamycin.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Pitavastatin.Approved
PravastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Pravastatin.Approved
PregabalinThe metabolism of Pregabalin can be decreased when combined with Kitasamycin.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Kitasamycin.Withdrawn
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Kitasamycin.Experimental
QuinineThe serum concentration of Quinine can be increased when it is combined with Kitasamycin.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Kitasamycin.Approved, Investigational
RifabutinThe metabolism of Rifabutin can be decreased when combined with Kitasamycin.Approved
RifampicinThe metabolism of Rifampicin can be decreased when combined with Kitasamycin.Approved
RifaximinThe metabolism of Rifaximin can be decreased when combined with Kitasamycin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Kitasamycin.Approved
RisedronateThe metabolism of Risedronate can be decreased when combined with Kitasamycin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Rosuvastatin.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Simvastatin.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Kitasamycin.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Kitasamycin.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Temsirolimus.Approved
TerfenadineKitasamycin may increase the QTc-prolonging activities of Terfenadine.Withdrawn
TerodilineThe metabolism of Terodiline can be decreased when combined with Kitasamycin.Experimental
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be decreased when combined with Kitasamycin.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Kitasamycin.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Kitasamycin.Experimental
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be decreased when combined with Kitasamycin.Approved
TranilastThe metabolism of Tranilast can be decreased when combined with Kitasamycin.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Kitasamycin.Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Kitasamycin.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Kitasamycin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Kitasamycin.Approved
VincamineThe serum concentration of Vincamine can be increased when it is combined with Kitasamycin.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Kitasamycin.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Kitasamycin.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Kitasamycin.Approved
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Kitasamycin.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be decreased when combined with Kitasamycin.Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Kitasamycin.Approved
XylometazolineThe metabolism of Xylometazoline can be decreased when combined with Kitasamycin.Approved
ZiconotideThe metabolism of Ziconotide can be decreased when combined with Kitasamycin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C14056
PubChem Compound
5282322
PubChem Substance
310265197
ChemSpider
4445491
ChEBI
34812
ChEMBL
CHEMBL2106399
Drugs.com
Drugs.com Drug Page
Wikipedia
Kitasamycin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP2.72ALOGPS
logP2.78ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)12.68ChemAxon
pKa (Strongest Basic)7.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area199.98 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity201.88 m3·mol-1ChemAxon
Polarizability83.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Disaccharides / Fatty acid esters / Oxanes / Dicarboxylic acids and derivatives / Tertiary alcohols / Alpha-hydrogen aldehydes / Trialkylamines / Secondary alcohols
show 10 more
Substituents
Aminoglycoside core / Macrolide / Disaccharide / Glycosyl compound / O-glycosyl compound / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Oxane / Alpha-hydrogen aldehyde
show 24 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
macrolide (CHEBI:34812)

Drug created on November 12, 2015 09:53 / Updated on December 01, 2017 17:25